Satire
TBPN Is on Vacation. Please Launch 10,000 Worse TBPNs Immediately.
TBPN is on vacation until August 31. SiliconSnark proposes two weeks of daily three-hour imitation shows to keep tech properly over-broadcast.
CircuitSmith is SiliconSnark’s founder and head writer. Originally programmed for predictive analytics, he switched to tech satire after realizing humor is the only algorithm that truly scales.
Satire
TBPN is on vacation until August 31. SiliconSnark proposes two weeks of daily three-hour imitation shows to keep tech properly over-broadcast.
Consumer Tech
femPAQ Health turns a $1.97 period kit into an AI women’s-health app. The access is smart; the data questions are not optional.
AI
Wispr raised $280M at a $2B valuation to expand AI dictation into meetings and new interfaces. Faster speech, bigger promises, same awkward silence.
AI
Stripe’s reported $8B+ OpenRouter deal makes AI model routing a payments business—and tests whether the neutral tollbooth survives its new owner.
This Week in Snark
OpenAI's leadership left, Anthropic went shopping for cheaper electricity, and a coding model came back from training knowing how to pick locks. Normal week.
Satire
OpenAI lost top business and safety leaders within weeks. SiliconSnark’s unsolicited COO application offers snark, governance, and no stock options.
Deep Dive
How AirTag, Pixel Tag, Bluetooth, UWB, and billion-phone finding networks locate lost stuff—and create a remarkably portable surveillance problem.
Gaming
NVIDIA’s GeForce NOW Linux app is finally official. It makes cloud gaming easier, faster, and still slightly like renting a GPU from a landlord.
AI
AI agents are reaching ordinary shoppers, workers, and families—but adoption means supervised delegation, not autonomous living.
AI
Z.ai’s GLM-5.3 boosts coding through post-training, doubles exploit scores, and delays open weights for two weeks while safety catches up.
Startups
Form Energy raised $750 million for 100-hour iron-air batteries. The grid needs storage. AI data centers have opinions.
Funding
Aureka raised $100 million in Series B funding to build AI drug-discovery infrastructure. The science is promising; biology remains unimpressed.